NASDAQ:IMUX

Immunic Stock Insider Trading

Healthcare > Biotechnology

Buy IMUX

*Your capital is at risk

$14.64

-0.130 (-0.88%)

At Close: Jul 13, 2026

Immunic Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 41.23M and sold 0 IMUX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	41.23M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 05, 2026 Buy	Stock Option A-Award	Congleton Jon Director	Director	25 370 Value: $375.5K
Jul 05, 2026 Buy	Stock Option A-Award	Neermann Joerg Director	Director	25 370 Value: $375.5K
Jul 05, 2026 Buy	Stock Option A-Award	Phillips Barclay A Director	Director	25 370 Value: $375.5K
Jul 05, 2026 Buy	Stock Option A-Award	Rudick Richard Alan Director	Director	25 370 Value: $375.5K
Jul 05, 2026 Buy	Stock Option A-Award	Skerjanec Simona Director	Director	25 370 Value: $375.5K
Jun 29, 2026 Buy	Stock Option A-Award	Bonney Michael W Director	Director	100 000 Value: $1.21M
Jun 29, 2026 Buy	Stock Option A-Award	Phillips Barclay A Director	Director	25 370 Value: $276.5K
Jun 29, 2026 Buy	Stock Option A-Award	Neermann Joerg Director	Director	25 370 Value: $276.5K
Jun 29, 2026 Buy	Stock Option A-Award	Howson Tamar D Director	Director	25 370 Value: $276.5K
Jun 29, 2026 Buy	Stock Option A-Award	Congleton Jon Director	Director	50 740 Value: $553.1K
Jun 29, 2026 Buy	Stock Option A-Award	Skerjanec Simona Director	Director	25 370 Value: $276.5K
Jun 29, 2026 Buy	Stock Option A-Award	Rudick Richard Alan Director	Director	25 370 Value: $276.5K
Jun 29, 2026 Buy	Stock Option A-Award	Tardio Jason President And COO	CEO / President	253 000 Value: $2.93M
Jun 29, 2026 Buy	Stock Option A-Award	Whaley Glenn Chief Financial Officer	C-Suite Officer	120 000 Value: $1.39M
Jun 29, 2026 Buy	Stock Option A-Award	Vitt Daniel Director	Director	445 000 Value: $5.16M
Jun 01, 2026 Buy	Common Stock J-Other	Lundgren Erik Officer	Officer	0 Value: $0
May 22, 2026 Buy	Stock Option A-Award	Lundgren Erik Chief Executive Officer	CEO / President	1 000 000 Value: $13.1M
May 16, 2026 Buy	Common Stock J-Other	Bonney Michael W	Director	0 Value: $0
Apr 24, 2026 Buy	Stock Option A-Award	Panzara Michael A. Chief Medical Officer	Officer	300 000 Value: $2.64M
Apr 24, 2026 Buy	Common Stock J-Other	Panzara Michael A. Officer	Officer	0 Value: $0
Mar 27, 2026 Buy	Common Stock J-Other	Congleton Jon	Director	0 Value: $0
Feb 17, 2026 Buy	Common Stock J-Other	Nagel Robert Thorvald	Director	0 Value: $0
Feb 17, 2026 Buy	Pre-Funded Warrants to Purchase Common Stock	Bvf Partners L P/il See Explanation Of Responses	Director	3 202 262 Value: $29.4M
Feb 17, 2026 Buy	Warrants to Purchase Common Stock	Bvf Partners L P/il See Explanation Of Responses	Director	3 202 262 Value: $29.4M
Feb 17, 2026 Buy	Common Stock, $0.0001 par value	Bvf Partners L P/il See Explanation Of Responses	Director	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMMUNIC INC.

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company i...

Read Full Profile Here